Saturday, 31 October 2026European Markets

DALATA HOTEL GP. And ACCOR Have A High Dividend Yield And Return On Equity In The Lodging Industry.

Loading stream...

(vianews) - dalata hotel gp. (dhg.ir) is among this list of stock assets with the highest dividend rate and return on equity on the lodging industry.

financial asset price forward dividend yield return on equity
dalata hotel gp. (dhg.ir) €4.32 2.72% 6.9%
accor (ac.pa) €40.60 2.05% 11.61%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. dalata hotel gp. (dhg.ir)

2.72% forward dividend yield and 6.9% return on equity

dalata hotel group plc owns, leases, and manages hotels under the maldron hotels and clayton hotels brand names in dublin, regional ireland, the united kingdom, and continental europe. it operates four-star hotels; and boutique hotels under the gibson hotel, the samuel hotel, hotel 7, and the belvedere hotel brands. the company also operates grain & grill restaurants; club vitae health and fitness clubs; and red bean roastery coffee outlets. in addition, it engages in financing, catering, hotel management, and property investment and holding activities. the company was formerly known as dhgl limited and changed its name to dalata hotel group plc in february 2014. dalata hotel group plc was founded in 2007 and is based in dublin, ireland.

earnings per share

as for profitability, dalata hotel gp. has a trailing twelve months eps of €0.4.

pe ratio

dalata hotel gp. has a trailing twelve months price to earnings ratio of 10.8. meaning, the purchaser of the share is investing €10.8 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.9%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on apr 4, 2024, the estimated forward annual dividend rate is 0.12 and the estimated forward annual dividend yield is 2.72%.

more news about dalata hotel gp..

2. accor (ac.pa)

2.05% forward dividend yield and 11.61% return on equity

accor sa operates a chain of hotels worldwide. it operates through three segments: management & franchise; services to owners; and hotel assets & others. the company owns, operates, manages, and franchises hotels. it also provides digital services to independent hotel operators through d-edge platform; gekko solutions for leisure and travel industry and large companies; and concierge and customized services through john paul, as well as hotel booking services; and other services in events, fine dining, and entertainment through paris society and potel & chabot platforms. in addition, the company offers distribution activities, such as private sales of hotel accommodation and luxury vacations through verychic platform; rental of private residences operated by onefinestay; and coworking spaces through wojo and mama works. further, it provides hotel management, procurement, cash management, it, and advertising services, as well as various advisory services. accor sa was founded in 1967 and is headquartered in issy-les-moulineaux, france.

earnings per share

as for profitability, accor has a trailing twelve months eps of €2.18.

pe ratio

accor has a trailing twelve months price to earnings ratio of 18.62. meaning, the purchaser of the share is investing €18.62 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.61%.

more news about accor.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com